Sanofi (NSDQ:SNY) has announced that olipudase alfa offered a sustained improvement in patients with acid sphingomyelinase deficiency (ASMD) in investigational long-term follow-up studies. ASDM is a rare progressive and potentially life-threatening disease with no authorized treatments. Patients in the trial had improvements in terms of lung function and reduced spleen and liver volumes. The research…